Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Mercuri

Showing results (61-70 of 96) with videos related to

Pageof 10
Sort By:
Journal of the American College of Cardiology|March 18, 2017
Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 TrialRaffaele De Caterina, Giulia Renda, Anthony P Carnicelli, et al.
European Heart Journal|January 10, 2019
Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trialGiuseppe Boriani, Christian T Ruff, Julia F Kuder, et al.
Circulation|February 18, 2017
Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic ValvesAnthony P Carnicelli, Raffaele De Caterina, Jonathan L Halperin, et al.
International Journal of Cardiology|June 20, 2017
First experience with edoxaban and atrial fibrillation ablation - Insights from the ENGAGE AF-TIMI 48 trialJan Steffel, Christian T Ruff, Rose A Hamershock, et al.
Circulation|July 4, 2018
Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 TrialOphelia Q P Yin, Elliott M Antman, Eugene Braunwald, et al.
Circulation|December 28, 2018
Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48David D Berg, Christian T Ruff, Petr Jarolim, et al.
The American Journal of Medicine|March 21, 2016
Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 TrialRobert P Giugliano, Christian T Ruff, Stephen D Wiviott, et al.
American Heart Journal|February 10, 2016
Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trialAlon Eisen, Robert P Giugliano, Christian T Ruff, et al.
Circulation. Cardiovascular Quality and Outcomes|May 12, 2018
Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction)James Aisenberg, Prapti Chatterjee-Murphy, Kathryn Friedman Flack, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|November 22, 2018
Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trialJan Steffel, Christian T Ruff, Eugene Braunwald, et al.
Pageof 10

Showing results (61-70 of 96) with videos related to

Sort By:
Pageof 10
Journal of the American College of Cardiology|March 18, 2017
Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 TrialRaffaele De Caterina, Giulia Renda, Anthony P Carnicelli, et al.
European Heart Journal|January 10, 2019
Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trialGiuseppe Boriani, Christian T Ruff, Julia F Kuder, et al.
Circulation|February 18, 2017
Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic ValvesAnthony P Carnicelli, Raffaele De Caterina, Jonathan L Halperin, et al.
International Journal of Cardiology|June 20, 2017
First experience with edoxaban and atrial fibrillation ablation - Insights from the ENGAGE AF-TIMI 48 trialJan Steffel, Christian T Ruff, Rose A Hamershock, et al.
Circulation|July 4, 2018
Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 TrialOphelia Q P Yin, Elliott M Antman, Eugene Braunwald, et al.
Circulation|December 28, 2018
Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48David D Berg, Christian T Ruff, Petr Jarolim, et al.
The American Journal of Medicine|March 21, 2016
Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 TrialRobert P Giugliano, Christian T Ruff, Stephen D Wiviott, et al.
American Heart Journal|February 10, 2016
Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trialAlon Eisen, Robert P Giugliano, Christian T Ruff, et al.
Circulation. Cardiovascular Quality and Outcomes|May 12, 2018
Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction)James Aisenberg, Prapti Chatterjee-Murphy, Kathryn Friedman Flack, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|November 22, 2018
Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trialJan Steffel, Christian T Ruff, Eugene Braunwald, et al.
Pageof 10